After defining the IG50 of neratinib, we selected HER2+ breast cancer cell line SUM190 and TNBC cell line SUM149 for RNAi screening because these cell lines showed near median IG50 concentration neratinib (Figure 1A) and demonstrated consistent tumorigenicity in nude mice. Here, ERBB2 is linked to breast carcinoma.